Biography for Tracy Staton
Tracy Staton, Senior Editor
Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at firstname.lastname@example.org or find her on LinkedIn.
Articles by Tracy Staton
Some industry watchers foresee biosimilars gutting Humira sales not too far into the future, though maker AbbVie disagrees.
Mylan and Perrigo's warring words have turned into warring lawsuits. After Perrigo sued last week to block Mylan's proposed takeover, saying the would-be buyer had misled shareholders, Mylan countersued, alleging its own set of "false and misleading statements."
Should Medicare be allowed to square off with pharma on drug prices? Presidential candidate Hillary Clinton was the latest politician to propose it, joining Democratic rival Sen. Bernie Sanders, President Obama--and a variety of other lawmakers before them.
On Monday, Hillary Clinton spooked biotech investors with a tweet promising to crack down on high drug prices. Shares plummeted. On Tuesday, she'll publicly unveil her pricing proposals in an Iowa speech, but until then, her campaign has offered some quick hints.
This could go down in pharma history as the week that drug pricing met pop culture. But this week won't be remembered as the one when drugmakers lost their long-standing pricing power in the U.S. That, at least, was the word from analysts and at least one top pharma CEO as politicians vowed a crackdown.
The ongoing controversies over rising drug prices have most Americans blaming drugmakers for their own rising pharmacy bills. The last thing pharma needs right now is a scandalous price hike to turn up the heat even further. But that's just what Turing Pharma and its CEO, Martin Shkreli, have on offer.
Celgene's Abraxane can't catch a break in England. Soon after losing coverage for pancreatic cancer on the country's dedicated Cancer Drugs Fund, the treatment got another thumbs-down from its official cost-effectiveness watchdogs.
Competition is heating up in the GLP-1 diabetes market, and Novo Nordisk is doing what it can to line up data behind its long-dominant drug, Victoza. The latest: A study pitting the brand against Sanofi's Lyxumia (lixisenatide), which is lining up for an FDA filing this quarter.
Merck KGaA has been working to turn itself around for years now, with consolidations, layoffs, reorgs and M&A all part of that effort. Now, the German company is rejigging top management in its healthcare business again.
Novo Nordisk is out trumpeting new data on its next-gen basal insulin Tresiba and a combo med, Xultophy. New studies to brag about are always good things. But they're particularly well-timed now, with the FDA on the verge of a decision on Tresiba--and analysts fairly certain that the drug will get the agency's stamp of approval.